Literature DB >> 12922099

Tularemia in BALB/c and C57BL/6 mice vaccinated with Francisella tularensis LVS and challenged intradermally, or by aerosol with virulent isolates of the pathogen: protection varies depending on pathogen virulence, route of exposure, and host genetic background.

Wangxue Chen1, Hua Shen, Ann Webb, Rhonda KuoLee, J Wayne Conlan.   

Abstract

In order to begin understanding the immunological basis for immunity to tularemia, and to establish a baseline for judging the efficacy of potential novel vaccines, the present study examined the ability of the live vaccine strain of Francisella tularensis (F. tularensis) LVS, to elicit immunity in mice against subsequent systemic and aerosol challenge with highly virulent strains of the pathogen. The results show, that infection with LVS protects BALB/c mice against systemic challenge with virulent Types A and B F. tularensis. In contrast, C57BL/6 mice vaccinated with LVS were only rendered immune to systemic challenge with Type B F. tularensis. Neither mouse strain immunized with LVS was able to resist aerosol challenge with Type A F. tularensis, and only immunized BALB/c mice withstood exposure to aerosols of Type B F. tularensis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12922099     DOI: 10.1016/s0264-410x(03)00386-4

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  66 in total

1.  Detoxified endotoxin vaccine (J5dLPS/OMP) protects mice against lethal respiratory challenge with Francisella tularensis SchuS4.

Authors:  Stephen H Gregory; Wilbur H Chen; Stephanie Mott; John E Palardy; Nicholas A Parejo; Sara Heninger; Christine A Anderson; Andrew W Artenstein; Steven M Opal; Alan S Cross
Journal:  Vaccine       Date:  2010-02-17       Impact factor: 3.641

2.  Antibodies contribute to effective vaccination against respiratory infection by type A Francisella tularensis strains.

Authors:  Gopi Mara-Koosham; Julie A Hutt; C Rick Lyons; Terry H Wu
Journal:  Infect Immun       Date:  2011-01-31       Impact factor: 3.441

3.  Toll-like receptor 2 is required for inflammatory responses to Francisella tularensis LVS.

Authors:  Jannet Katz; Ping Zhang; Michael Martin; Stefanie N Vogel; Suzanne M Michalek
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

4.  Mice Housed at Elevated Vivarium Temperatures Display Enhanced T-cell Response and Survival to Francisella tularensis.

Authors:  Robert L Rubin
Journal:  Comp Med       Date:  2017-12-01       Impact factor: 0.982

5.  Identification of a dominant CD4 T cell epitope in the membrane lipoprotein Tul4 from Francisella tularensis LVS.

Authors:  Michael D Valentino; Lucinda L Hensley; Denise Skrombolas; Pamela L McPherson; Matthew D Woolard; Thomas H Kawula; Jeffrey A Frelinger; John G Frelinger
Journal:  Mol Immunol       Date:  2009-02-23       Impact factor: 4.407

6.  The immunologically distinct O antigens from Francisella tularensis subspecies tularensis and Francisella novicida are both virulence determinants and protective antigens.

Authors:  Rebecca M Thomas; Richard W Titball; Petra C F Oyston; Kate Griffin; Emma Waters; Paul G Hitchen; Stephen L Michell; I Darren Grice; Jennifer C Wilson; Joann L Prior
Journal:  Infect Immun       Date:  2006-10-30       Impact factor: 3.441

7.  Differential ability of novel attenuated targeted deletion mutants of Francisella tularensis subspecies tularensis strain SCHU S4 to protect mice against aerosol challenge with virulent bacteria: effects of host background and route of immunization.

Authors:  J Wayne Conlan; Hua Shen; Igor Golovliov; Carl Zingmark; Petra C F Oyston; Wangxue Chen; Robert V House; Anders Sjöstedt
Journal:  Vaccine       Date:  2009-12-16       Impact factor: 3.641

8.  Direct and indirect impairment of human dendritic cell function by virulent Francisella tularensis Schu S4.

Authors:  Jennifer C Chase; Jean Celli; Catharine M Bosio
Journal:  Infect Immun       Date:  2008-11-03       Impact factor: 3.441

9.  Liposomal gD ectodomain (gD1-306) vaccine protects against HSV2 genital or rectal infection of female and male mice.

Authors:  K Olson; P Macias; S Hutton; W A Ernst; G Fujii; J P Adler-Moore
Journal:  Vaccine       Date:  2009-10-14       Impact factor: 3.641

10.  Infection with Francisella tularensis LVS clpB leads to an altered yet protective immune response.

Authors:  Lydia M Barrigan; Shraddha Tuladhar; Jason C Brunton; Matthew D Woolard; Ching-ju Chen; Divey Saini; Richard Frothingham; Gregory D Sempowski; Thomas H Kawula; Jeffrey A Frelinger
Journal:  Infect Immun       Date:  2013-03-25       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.